Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach;
however, it has shown limited success in some cancers including colorectal cancer (CRC) …

Despite recent advances in colorectal cancer (CRC) treatment, a large proportion of patients
show limited responses to therapies, especially in advanced stages. There is an urgent …

Regulatory T cells (Tregs) can be antitumorigenic or pro-tumorigenic in colorectal cancer
(CRC) depending on the presence of different Treg subsets with various …

Purpose Expansion of CD8+ cytotoxic Tlymphocytes is a prerequisite for anti-cancer
immune activity and has gained interest in the era of immune checkpoint therapy. Methods …

Purpose Many patients who present with early-stage colorectal cancer (International Union
Against Cancer TNM stages I and II) are nevertheless at high risk of relapse. We …

CD8+ T cell activation via immune checkpoint blockade (ICB) is successful in microsatellite
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …

Objective As the development and progression of colorectal cancer (CRC) are known to be
affected by the immune system, cell subsets such as T cells, natural killer (NK) cells, and …

Microsatellite stable colorectal cancers (MSS-CRC) are resistant to anti-PD-1/PD-L1 therapy
but the combination of immune checkpoints inhibitors (ICI) could be a clue to reverse …

Background Immune cells play a key role in cancer progression and treatment. It is unclear
whether the clinicopathologic characteristics and blood indexes of colorectal cancer (CRC) …

Background The immunoscore (IS), an index based on the density of CD3+ and CD8+ tumor-
infiltrating lymphocytes (TILs) in the tumor center (CT) and invasive margin (IM), has gained …